Free Trial
Catherine Schulte

Catherine Schulte Analyst Performance

Senior Research Analyst - Life Sciences & Diagnostics at Robert W. Baird

Catherine Schulte is a stock analyst at Robert W. Baird focused in the medical sector, covering 13 publicly traded companies. Over the past year, Catherine Schulte has issued 28 stock ratings, including strong buy, buy, and hold recommendations. While full access to Catherine Schulte's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Catherine Schulte's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
42 Last 4 Years
Buy Recommendations
77.50% 31 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy2.5%1 ratings
Buy75.0%30 ratings
Hold22.5%9 ratings
Sell0.0%0 ratings

Out of 40 total stock ratings issued by Catherine Schulte at Robert W. Baird, the majority (75.0%) have been Buy recommendations, followed by 22.5% Hold and 2.5% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
53.8% of companies on NASDAQ
7 companies
NYSE
46.2% of companies on NYSE
6 companies

Catherine Schulte, an analyst at Robert W. Baird, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
12 companies
92.3%
Services
1 company
7.7%

Catherine Schulte of Robert W. Baird specializes in stock coverage within the Medical sector, with additional focus on Services companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
38.5%
MED PRODUCTS
2 companies
15.4%
MED INSTRUMENTS
2 companies
15.4%
MEDICAL SERVICES
2 companies
15.4%
SERVICES – HEALTH
1 company
7.7%
MEDICAL INFO SYS
1 company
7.7%

About Catherine Schulte

Catherine Ramsey Schulte is Baird’s Senior Research Analyst covering Life Sciences & Diagnostics. Prior to joining Baird in 2014, she worked at Medtronic, Pathfinder Technologies and Vanderbilt University Medical Center. She also was an equity research intern at Avondale Partners, LLC. In the 2019 StarMine Analyst Awards by Refinitiv, Catherine was recognized as the No. 1 stock picker in Life Sciences Tools & Services. Catherine received a BSE in Biomedical Engineering from Duke University.
Follow on LinkedIn

Catherine Schulte's Ratings History at Robert W. Baird

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
5/26/2026Boost Price Target$115.01$156.00Outperform
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
5/11/2026Lower Price Target$1,123.08$1,194.00Neutral
Qiagen N.V. stock logo
QGEN
Qiagen
4/29/2026Set Price Target$33.98$43.00Outperform
Qiagen N.V. stock logo
QGEN
Qiagen
4/29/2026Upgrade$33.61$43.00Strong-Buy
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
4/24/2026Lower Price Target$466.93$639.00Outperform
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
2/27/2026Boost Price Target$19.24$28.00Outperform
GRAIL, Inc. stock logo
GRAL
GRAIL
2/17/2026Initiated Coverage$97.50$113.00Outperform
Tempus AI, Inc. stock logo
TEM
Tempus AI
2/17/2026Initiated Coverage$51.95$59.00Outperform
Guardant Health, Inc. stock logo
GH
Guardant Health
2/17/2026Initiated Coverage$104.85$120.00Outperform
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
2/17/2026Initiated Coverage$20.62$26.00Outperform
Caris Life Sciences, Inc. stock logo
CAI
Caris Life Sciences
2/17/2026Initiated Coverage$20.80$26.00Outperform
Guardant Health, Inc. stock logo
GH
Guardant Health
2/17/2026Initiated Coverage$107.11$120.00Outperform
GRAIL, Inc. stock logo
GRAL
GRAIL
2/17/2026Initiated Coverage$99.03$113.00Outperform
Tempus AI, Inc. stock logo
TEM
Tempus AI
2/17/2026Initiated Coverage$52.56$59.00Outperform
Avantor, Inc. stock logo
AVTR
Avantor
2/12/2026Set Price Target$9.66$11.00
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
11/25/2025Boost Price Target$153.24$165.00Outperform
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
11/4/2025Boost Price Target$70.96$88.00Outperform
Avantor, Inc. stock logo
AVTR
Avantor
10/24/2025Boost Price Target$15.49$17.00Outperform
Danaher Corporation stock logo
DHR
Danaher
10/22/2025Set Price Target$217.24$247.00
Danaher Corporation stock logo
DHR
Danaher
10/15/2025Boost Price Target$211.96$236.00Outperform
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
8/28/2025Boost Price Target$122.90$142.00Outperform
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
8/4/2025Boost Price Target$1,198.77$1,230.00Neutral
Avantor, Inc. stock logo
AVTR
Avantor
8/4/2025Lower Price Target$11.37$15.00Outperform
Avantor, Inc. stock logo
AVTR
Avantor
7/28/2025Boost Price Target$14.20$18.00Outperform
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
7/28/2025Boost Price Target$1,265.55$1,210.00Neutral
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
7/24/2025Boost Price Target$466.84$567.00Outperform
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
7/18/2025Lower Price Target$425.28$553.00Outperform
Danaher Corporation stock logo
DHR
Danaher
7/18/2025Boost Price Target$194.81$226.00Outperform
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
5/22/2025Lower Price Target$109.08$140.00Outperform
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
5/13/2025Lower Price Target$2.12$2.00Neutral
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
5/2/2025Boost Price Target$47.16$72.00Outperform
Avantor, Inc. stock logo
AVTR
Avantor
4/28/2025Lower Price Target$12.93$17.00Outperform
Thermo Fisher Scientific Inc. stock logo
TMO
Thermo Fisher Scientific
4/24/2025Lower Price Target$432.31$573.00Outperform
Danaher Corporation stock logo
DHR
Danaher
4/23/2025Lower Price Target$192.06$225.00Outperform
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
4/22/2025Lower Price Target$971.31$1,034.00Neutral
Qiagen N.V. stock logo
QGEN
Qiagen
4/21/2025Boost Price Target$42.84$45.26Neutral
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
2/27/2025Lower Price Target$134.51$159.00Outperform
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2/26/2025Downgrade$3.14$3.00Neutral
Bio-Techne Corp stock logo
TECH
Bio-Techne
2/19/2025Downgrade$65.29$68.00Neutral
Mettler-Toledo International, Inc. stock logo
MTD
Mettler-Toledo International
2/10/2025Boost Price Target$1,390.00$1,369.00Neutral
I was right about SpaceX (Ad)

Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel

See how to claim your stake in SpaceX before the public can
Danaher Corporation stock logo
DHR
Danaher
1/28/2025Lower Price Target$248.46$268.00Overweight